The renaissance of psychedelics in modern psychiatry: a new breakthrough or the myth of a “magic bullet”?
Neurology Bulletin March 15, 2025 V. Skryabin
Interest in psychedelic research has surged, with compounds like psilocybin, MDMA, DMT, and LSD showing rapid therapeutic effects for depression, PTSD, anxiety, and OCD, especially when paired with psychotherapy. However, many studies are methodologically weak, lacking adequate placebo controls and standardized dosing, using small samples, and being influenced by contextual factors. This article critically reviews the evidence, discusses historical context including early Russian work with ketamine by E.M. Krupitsky, and urges Russian psychiatrists to assess the data carefully and develop a balanced approach that accounts for evidence quality and local regulations.